The concept of FDG-PET endophenotype in Alzheimer's disease

NYU Langone Medical Center, NYU School of Medicine, New York, NY, USA.
Neurological Sciences (Impact Factor: 1.45). 06/2011; 32(4):559-69. DOI: 10.1007/s10072-011-0633-1
Source: PubMed


Often viewed as a potential tool for preclinical diagnosis in early asymptomatic stages of Alzheimer's disease (AD), the term "endophenotype" has acquired a recent popularity in the field. In this review, we analyze the construct of endophenotype-originally designed to discover genes, and examine the literature on potential endophenotypes for the late-onset form of AD (LOAD). We focus on the [18F]-fluoro-2-deoxyglucose (FDG) PET technique, which shows a characteristic pattern of hypometabolism in AD-related regions in asymptomatic carriers of the ApoE E4 allele and in children of AD mothers. We discuss the pathophysiological significance and the positive predictive accuracy of an FDG-endophenotype for LOAD in asymptomatic subjects, and discuss several applications of this endophenotype in the identification of both promoting and protective factors. Finally, we suggest that the term "endophenotype" should be reserved to the study of risk factors, and not to the preclinical diagnosis of LOAD.

4 Reads
  • Source
    • "In our work, we have proposed an inflammatory endophenotype of AD [6,7] as well as a neurotrophic factor endophenotype of AD [8] based on blood-based biomarkers. Other endophenotypes have now been proposed based on neuropathology [9], neuroimaging [10,11], genetics [12], and cerebrospinal fluid markers [13]. Neuropsychiatric endophenotypes of AD have also been proposed, which included depression [14] and is consistent with our data. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is a devastating public health problem that affects over 5.4 million Americans. Depression increases the risk of Mild Cognitive Impairment (MCI) and AD. By understanding the influence of depression on cognition, the potential exists to identify subgroups of depressed elders at greater risk for cognitive decline and AD. The current study sought to: 1) clinically identify a sub group of geriatric patients who suffer from depression related cognitive impairment; 2) cross validate this depressive endophenotype of MCI/AD in an independent cohort. Data was analyzed from 519 participants of Project FRONTIER. Depression was assessed with the GDS30 and cognition was assessed using the EXIT 25 and RBANS. Five GDS items were used to create the Depressive endophenotype of MCI and AD (DepE). DepE was significantly negatively related to RBANS index scores of Immediate Memory (B=-2.22, SE=.37, p<0.001), visuospatial skills (B=-1.11, SE=0.26, p<0.001), Language (B=-1.03, SE=0.21, p<0.001), Attention (B=-2.56, SE=0.49, p<0.001), and Delayed Memory (B=-1.54, SE = 037, p<0.001), and higher DepE scores were related to poorer executive functioning (EXIT25; B=0.65, SE=0.19, p=0.001). DepE scores significantly increased risk for MCI diagnosis (odds ratio [OR] = 2.04; 95% CI=1.54-2.69). Data from 235 participants in the TARCC (Texas Alzheimer's Research & Care Consortium) were analyzed for cross-validation of findings in an independent cohort. The DepE was significantly related to poorer scores on all measures, and a significantly predicted of cognitive change over 12- and 24-months. The current findings suggest that a depressive endophenotype of MCI and AD exists and can be clinically identified using the GDS-30. Higher scores increased risk for MCI and was cross-validated by predicting AD in the TARCC. A key purpose for the search for distinct subgroups of individuals at risk for AD and MCI is to identify novel treatment and preventative opportunities.
    PLoS ONE 07/2013; 8(7):e68848. DOI:10.1371/journal.pone.0068848 · 3.23 Impact Factor
  • Source
    • "As apolipoprotein E (APOE) genotype was available only in 23 out of 36 patients, we could not include it as a nuisance variable in SPM analyses. Indeed, it has been demonstrated that APOE␧4 carriers may show peculiar, and more extensive, regions of hypometabolism with respect to the general AD population (During et al., 2011; Mosconi et al., 2004a; Reiman et al., 2001). For this reason, the 23 patients whose APOE genotype was available were divided into APOE ␧4ϩ (n ϭ 13) and APOE ␧4Ϫ (n ϭ 10) subgroups and all IRCA analyses were repeated in the 2 subgroups (see Supplementary data). "
    [Show abstract] [Hide abstract]
    ABSTRACT: We explored resting-state metabolic connectivity in prodromal Alzheimer's disease (pAD) patients and in healthy controls (CTR), through a voxel-wise interregional correlation analysis of 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) by means of statistical parametric mapping. Baseline 18F-fluorodeoxyglucose-positron emission tomography of 36 patients with amnestic mild cognitive impairment who converted to Alzheimer's disease (AD) dementia after an average time of 2 years (pAD) and of 105 CTR were processed. The area of hypometabolism in pAD showed less metabolic connectivity in patients than in CTR (autocorrelation and correlation with large temporal and frontal areas, respectively). pAD patients showed limited correlation even in selected nonhypometabolic areas, including the hippocampi and the dorsolateral prefrontal cortex (DLFC). On the contrary, in CTR group correlation was highlighted between hippocampi and precuneus/posterior cingulate and frontal cortex, and between dorsolateral prefrontal cortex and caudate nuclei and parietal cortex. The reduced metabolic connections both in hypometabolic and nonhypometabolic areas in pAD patients suggest that metabolic disconnection (reflecting early diaschisis) may antedate remote hypometabolism (early sign of synaptic degeneration).
    Neurobiology of aging 02/2012; 33(11):2533-50. DOI:10.1016/j.neurobiolaging.2012.01.005 · 5.01 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Identifying risk factors for Alzheimer's disease, such as carrying the APOE-4 allele, and understanding their contributions to disease pathophysiology or clinical presentation is critical for establishing and improving diagnostic and therapeutic strategies. A first-degree family history of Alzheimer's disease represents a composite risk factor, which reflects the influence of known and unknown susceptibility genes and perhaps non-genetic risks. There is emerging evidence that investigating family history risk associated effects may contribute to advances in Alzheimer's disease research and ultimately clinical practice.
    Neuropsychology Review 02/2012; 22(3):298-309. DOI:10.1007/s11065-012-9193-2 · 4.59 Impact Factor
Show more